OrthoPediatrics’ CEO David Bailey commented “I’m especially proud of our newest clinic in Indy! As an Indiana-based company, being able to bring specialty care to KIDS in our Hoosier state represents ...
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH ...
The addition of two new members - Theratechnologies Inc. for Canada and Innovative Medicines Group (IMG) for LATAM - brings the total number of countries covered by WODA to 158 and extends its reach ...
Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue. Management to Host ...
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve ...
Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...
TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and ...
LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...
Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with both the Nasdaq minimum bid price rule and Nasdaq’s periodic financial reporting rule.” As the ...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
scPharmaceuticals expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at ...
Oryzon has been invited to participate at the 8th Sachs Annual Neuroscience Innovation Forum, which will be held on January 12 at the Marines’ Memorial Club in San Francisco (USA). The company will ...
The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $4.25 million. Calidi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback